Showing 5691-5700 of 9511 results for "".
- Almirall, LLC is the New Name of Aquahttps://practicaldermatology.com/news/aqua-is-now-almirall/2457551/Almirall, LLC is the new name of Aqua Pharmaceuticals. Almirall, LLC is part of the larger Almirall, S.A. family, an internationally-recognized global dermatology pharmaceutical company, with a strong focus on skin health. The name change, was announced jointly by Almirall LLC Pre
- New from xMedica: Aesthetics Conference Features Energy Based Treatments for Male and Female Sexual Wellnesshttps://practicaldermatology.com/news/new-from-xmedica-aesthetics-conference-features-energy-based-treatments-for-male-and-female-sexual-wellness/2457553/Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding goal of this unique conference is to present factual data in a CME setting to address this new are
- Amgevita, Amgen's Biosimilar Adalimumab, Launches in Europehttps://practicaldermatology.com/news/amgevita-amgens-biosimilar-adalimumab-launches-in-europe/2457555/Amgen's Amgevita, a biosimilar to adalimumab, has launched in markets across Europe. Amgevita is the first adalimumab biosimilar to be approved by the European Commission (EC) and is authorized for the treatment of inflammatory diseases in adults, including moder
- Almirall's Seysara Set to Shake Up US Acne Markethttps://practicaldermatology.com/news/almiralls-seysara-set-to-shake-up-us-acne-market/2457557/The US Food and Drug Administration’s approval of Almirall’s Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ages nine and older is set to shake up the currently stagnant acne market due to its ease of adminis
- Residents of Distinction Attend 2018 Coastal Dermatology Symposiumhttps://practicaldermatology.com/news/residents-of-distinction-attend-2018-coastal-dermatology-symposium/2457554/As part of the dermMentors Resident of Distinction Award program, sponsored by Beiersdorf Inc., five dermatology residents attended the 14th Annual Coastal Dermatology Symposium, held in Monterey, CA October 3-6, 2018. The 2018 dermMentors™
- Real-world Evaluation Study Confirms Benefits of ARTAS iX Robotic Hair Restoration Systemhttps://practicaldermatology.com/news/real-world-evaluation-study-confirms-benefits-of-artas-ix-robotic-hair-restoration-system/2457560/Restoration Robotics, Inc. (NASDAQ: HAIR), the global leader in robotic hair restoration, today announced results from a real-world evaluation study. The new ARTAS iX™ Robotic Hair Restoration System demonstrates clinical efficiency in hair harvesting and implanta
- Aclaris Acquires Rhofade from Allerganhttps://practicaldermatology.com/news/aclaris-acquires-rhofade-from-allergan/2457561/Aclaris Therapeutics, Inc. has entered into a definitive asset purchase agreement with Allergan Sales, LLC to acquire worldwide rights to Rhofade® (oxymetazoline hydrochloride) cream, 1% and additional intellectual property. The acquisition includes an exclusive license to certain intel
- Endo Presents Data on the Perception and Measurement of Cellulite Severity at ASDS Meetinghttps://practicaldermatology.com/news/endo-presents-data-on-the-perception-and-measurement-of-cellulite-severity-at-asds-meeting/2457568/The new Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a reliable tool for evaluating cellulite severity of the buttocks and thighs and correlates well with the Patient Reported Photonumeric Cellulite Severity Scale, according to research presented by
- Pre-conditioning Added to Sebacia Microparticles Enhances Outcomeshttps://practicaldermatology.com/news/pre-conditioning-added-to-sebacia-microparticles-enhances-outcomes/2457567/Using pre-conditioning in conjunction with Sebacia Microparticles for treatment of acne leads to enhanced outcomes, new data suggest. In fact, results from a real-world, pre-conditioning registry trial in Europe demonstrate that the combination of pre-conditioning followed by Sebacia Mi
- Study: Positive Safety and Tolerability Results for Ortho Dermatologics' Altreno for Acnehttps://practicaldermatology.com/news/study-positive-results-for-ortho-dermatologics-altrenos-safety-and-tolerability-for-acne/2457569/Ortho Dermatologics shared results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of Altreno (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topi